*A corporate client of Hybridan LLP
Dish of the day
No joiners today
Off the menu
No leavers today
What’s cooking in the IPO kitchen?
Upon Admission to AIM, Nightcap will acquire The London Cocktail Club Limited (the “London Cocktail Club”), which is an award winning independent operator of ten individually themed cocktail bars in nine London locations and one location in Bristol. Offer TBC Due mid Jan.
HSS Hire Group, HSS.L transfer from Main to Aim. Mkt Cap c. GBP70m. Recently raised GBP52.6m. Leading supplier of tool and equipment for hire in the United Kingdom and Ireland and has provided equipment hire services in the United Kingdom for more than 60 years, primarily focusing on the B2B market. Due 14 Jan.
VH Global Sustainable Energy Opportunities plc, a closed-ended investment Company focused on making sustainable energy infrastructure investments, today announces intends to launch an initial public offering of shares on the Official List (Premium) of the Main Market of the London Stock Exchange. Due by Early Feb.
Petro Matad 3.85p GBP26.2m (AIM:MATD)
The Mongolian oil company, provides the following update on its application to secure an Exploitation Licence for the Heron oil discovery in Block XX, eastern Mongolia.
The Block XX Exploitation Licence application has progressed with the meeting of the Mineral Resource Professional Council (MRPC) taking place. The meeting was held virtually due to a Covid-19 lockdown currently in place in Mongolia. MRPC reviewed Petro Matad’s Heron Reserves Report and approved the submission without alteration.
Following the MRPC meeting, Petro Matad immediately wrote to the Ministry of Mining and Heavy Industry requesting the appointment of auditors who must now review the Plan of Development before this document is submitted to the Mineral Resources and Petroleum Authority of Mongolia (MRPAM) and to MRPC for review and final approval. Preparation of the Plan of Development has already been completed by the Company and the documentation is ready for the audit and review process. Petro Matad has also prepared its formal application to MRPAM for the Exploitation Area. Under the law, the Exploitation Area is to be determined by mutual agreement between MRPAM and the Company.
Westmount Energy 20.5p GBP29.53m (AIM:WTE)
Westmount notes the announcement by the Maritime Administration Department, Guyana, dated 1st January 2021, that the Stena Carron drillship has arrived on location at the Bulletwood-1 wellsite on the Canje Block, offshore Guyana and has commenced drilling operations.
As previously announced, Westmount holds an indirect interest in the Canje Block as a result of its circa 7.2% interest in the issued share capital of JHI Associates Inc. (JHI). The Canje Block is currently operated by an ExxonMobil subsidiary, Esso Exploration & Production Guyana Limited (35%), with Total (35%), JHI (17.5%) and Mid-Atlantic Oil & Gas Inc. (12.5%) as partners.
Previously published information by JHI indicates that Bulletwood-1 is a 500 MMbbl oil prospect targeting a Liza look-alike, confined channel complex, of Late Cretaceous, Campanian, age. Based upon the announcement by the Maritime Administration Department drilling operations are scheduled to be completed at Bulletwood-1 on or before the 23rd February 2021.
As a result of a 2018 farm-out to Total, JHI is carried for the drilling of up to four wells, including Bulletwood-1, and is funded for the drilling of additional wells.
One Heritage Group* 12.25p GBP3.7m (OHG.L)
The UK-based residential developer focused on the North West of England announced their maiden acquisition since their December IPO. They have exercised an option to acquire a site on Bank Street, Sheffield. The total consideration paid is GBP879,770 in cash. The site is located within the city centre on Bank Street and it is on the edge of the retail and commercial centre in the Cathedral District, only a 15-minute walk from the train station. The site has planning permission for 21 self-contained apartments, but management are likely to resubmit the planning to increase the number to 23. The Company expects the final development cost to be GBP2.9 million with a Gross Development Value (GDV) of GBP3.6 million once the revised planning permission is in place. Management is expecting to start on site by the first quarter of 2021 with completion anticipated for the first quarter of 2022.
Update in respect of its wholly owned subsidiary, Pharm 2 Farm Limited .
Further to the announcement on 29 December 2020 advising of the likely shipping date of the P2F face mask manufacturing machine, the Company advised that the plant was loaded and dispatched from Spain yesterday (4 January 2021).
It is likely to arrive in Nottingham at the earliest on or about 8 January 2021, subject to any routine traffic or customs delays. The Company expects to provide a further update on expected production levels once the machine has been commissioned and an assessment has been made.
GlobalData 1365p GBP1.6bn (AIM:DATA)
The global provider of data, analytics and insights, is today announcing the following Board changes.
Bernard Cragg will stand down as Chairman after six years of service as a Non Executive Director followed by four years as Chairman at the close of the forthcoming AGM to be held on 20 April 2021. The Board announces that his successor as Independent Non Executive Chairman will be Murray Legg who will assume the role with effect from the AGM.
Murray has been a Non Executive Director of the Company and Chairman of the Audit Committee since 2016.He is a chartered accountant with over 35 years of audit and advisory experience at PwC where he was a Partner for 24 years. During this time he had senior management, governance and market facing roles with major UK companies across a range of industry sectors including the media sector.
In addition, it is the Board’s intention to appoint additional Non Executives in due course, one of whom will succeed Murray as Chairman of the Audit Committee, and the Company will provide an update accordingly.
Renalytix AI 602.5p GBP434m (AIM:RENX)
The artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care , and DaVita (NYSE: DVA) are partnering on a program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). The program is expected to improve patient outcomes and provide meaningful cost reductions for health care providers and payors by enabling earlier intervention for patients with early-stage kidney disease (stages 1, 2 and 3) through actionable risk assessments and end-to-end care management.
The AIM listed specialist investor focused on a more sustainable economy, today provides an update on the development of its assets under discretionary and advisory management for the first quarter of its financial year.
On 31 December 2020, the Company’s AUM totalled GBP25.2 billion, representing an increase of 24.8% for the quarter and a new record high.
Solid State 745p GBP63.6m (AIM:SOLI)
The AIM listed manufacturer of computing, power and communications products, and value added supplier of electronic and opto-electronic components, is pleased to announce that its Manufacturing division, Steatite, has secured a GBP2.2m contract to supply in excess of 1000 computer systems.
The units supplied by Steatite will be part of a rugged computing and display system for a customer in the transportation sector. Delivery is expected over a 12-24 month period, starting early in the financial year 2021/2022.
Getech 16.25p GBP6.1m (AIM:GTC)
Getech, a provider of data, knowledge and software to the energy industry, has secured a multi-year licence agreement for its Globe product with a national energy company.
The agreement follows completion of the customer’s first year as a Globe user and adds GBP563,000 to Getech’s current orderbook.
An additional option has also been agreed that enables the customer to purchase other Getech data modules, which would enhance and extend its use of Globe.
Destiny Pharma 75p GBP44.8m (AIM:DEST)
The clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces that its XF-73 Phase 2b clinical trial was fully recruited by 31 December 2020, meeting the target timeline set for the programme.
If you would like to unsubscribe, please email [email protected] with “unsubscribe me”.
0203 764 2344
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of section B of annex I to Directive 2014/65/EU (“MIFID II Directive”); or (ii) investment research as defined in article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.